Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Glycopyrrolate bromide: Phase III started

    Sumitomo Dainippon Pharma Co. Ltd.(Tokyo:4506), Osaka, Japan Product: Glycopyrrolate bromide (SUN-101) (formerly EP-101) Business: Pulmonary Molecular target: Muscarinic receptor Description: Inhaled formulation of …

    Published on 3/16/2015
  • GVAX Pancreas cancer vaccine: Phase II started

    Aduro Biotech Inc., Berkeley, Calif. Product: GVAX Pancreas cancer vaccine Business: Cancer Molecular target: NA Description: Allogeneic cancer vaccine engineered to secrete GM-CSF Indication: Treat pancreatic cancer …

    Published on 3/16/2015
  • Nalbuphine ER: Phase II/III started

    Endo International plc(NASDAQ:ENDP; TSX:ENL), Dublin, Ireland Trevi Therapeutics Inc., New Haven, Conn. Product: Nalbuphine ER (T111) Business: Dermatology Molecular target: Mu opioid receptor (MOR) (OPRM1); Kappa …

    Published on 3/16/2015
  • Oral neratinib: Phase II started

    Puma Biotechnology Inc.(NYSE:PBYI), Los Angeles, Calif. Pfizer Inc.(NYSE:PFE), New York, N.Y. Product: Oral neratinib (HKI-272, PB272) Business: Cancer Molecular target: Epidermal growth factor receptor 1 (EGFR1) (HER1)…

    Published on 3/16/2015
  • PEG-P-INF alfa-2b: Completed Phase III enrollment

    AOP Orphan Pharmaceuticals AG, Vienna, Austria PharmaEssentia Corp.(GreTai-E:6446), Taipei, Taiwan Product: PEG-P-INF alfa-2b, Ropeginterferon alfa 2b (AOP2014, P1101) Business: Hematology Molecular target: NA …

    Published on 3/16/2015
  • TRV027: Phase IIb ongoing

    Trevena Inc.(NASDAQ:TRVN), King of Prussia, Pa. Product: TRV027 (formerly TRV120027) Business: Cardiovascular Molecular target: Angiotensin II type 1 (AT1) receptor (AGTR1) Description: Dual-acting ligand that inhibits …

    Published on 3/16/2015
  • Vesigenurtacel-L: Phase I/II amended

    Heat Biologics Inc.(NASDAQ:HTBX), Chapel Hill, N.C. Product: Vesigenurtacel-L (HS-410) Business: Cancer Molecular target: Heat shock 90 kDa protein beta 1 (Hsp90B1) (GP96) (GRP94) Description: Bladder cancer cell line …

    Published on 3/16/2015
  • Zmapp: Phase I/II started

    Defyrus Inc., Toronto, Ontario Mapp Biopharmaceutical Inc., San Diego, Calif. Product: Zmapp Business: Infectious Molecular target: NA Description: Combination of 3 mAbs targeting Ebola glycoproteins GP1 and GP2 …

    Published on 3/16/2015
  • APN401: Phase I started

    Apeiron Biologics AG, Vienna, Austria Product: APN401 Business: Cancer Molecular target: Casitas B cell lymphoma-b (Cbl-b) Description: Autologous peripheral blood mononuclear cells (PBMCs) silenced ex vivo for the …

    Published on 3/9/2015
  • Cenderitide: Phase II started

    Capricor Therapeutics Inc.(OTCQB:CAPR), Beverly Hills, Calif. Product: Cenderitide (formerly CD-NP) Business: Cardiovascular Molecular target: Natriuretic peptide receptor A (NPR1) (NPRA); Natriuretic peptide receptor B…

    Published on 3/9/2015
  • EBOV GP vaccine: Phase I started

    Novavax Inc.(NASDAQ:NVAX), Gaithersburg, Md. Product: EBOV GP vaccine, Ebola GP Vaccine Business: Infectious Molecular target: NA Description: Recombinant glycoprotein nanoparticle vaccine based on the cluster 3 gene …

    Published on 3/9/2015
  • Glycerol phenylbutyrate: Phase IV started

    Hyperion Therapeutics Inc.(NASDAQ:HPTX), South San Francisco, Calif. Valeant Pharmaceuticals International Inc.(TSX:VRX; NYSE:VRX), Laval, Quebec Product: Glycerol phenylbutyrate (HPN-100, Ravicti)) (formerly GT4P) …

    Published on 3/9/2015
  • Glycopyrrolate bromide: Phase III started

    Sumitomo Dainippon Pharma Co. Ltd.(Tokyo:4506), Osaka, Japan Product: Glycopyrrolate bromide (SUN-101) (formerly EP-101) Business: Pulmonary Molecular target: Muscarinic receptor Description: Inhaled formulation of …

    Published on 3/9/2015
  • Hepatitis B vaccine: Phase IIb/III started

    Abivax S.A.S., Paris, France Product: Hepatitis B vaccine (ABX203) Business: Infectious Molecular target: NA Description: Therapeutic vaccine composed of recombinant hepatitis B surface antigen (HBsAg) and hepatitis B …

    Published on 3/9/2015
  • Heplisav: Phase III ongoing

    Dynavax Technologies Corp.(NASDAQ:DVAX), Berkeley, Calif. Product: Heplisav (V270) Business: Infectious Molecular target: Toll-like receptor 9 (TLR9) Description: Hepatitis B surface antigen (HBsAg) given with …

    Published on 3/9/2015
  • HESPECTA: Phase I/II started

    ISA Pharmaceuticals B.V., Leiden, the Netherlands Product: HESPECTA Business: Cancer Molecular target: NA Description: Conjugate of 2 HPV type 16 E6 synthetic long peptides (SLPs) covalently linked to Amplivant, a …

    Published on 3/9/2015
  • Imilecleucel-T: Completed Phase IIb enrollment

    Opexa Therapeutics Inc.(NASDAQ:OPXA), The Woodlands, Texas Product: Imilecleucel-T (Tcelna) (formerly Tovaxin) Business: Autoimmune Molecular target: T cell receptor (TCR) Description: Patient-specific myelin reactive T…

    Published on 3/9/2015
  • IV Bendavia: Phase I/II started

    Stealth BioTherapeutics Inc., Newton, Mass. Product: IV Bendavia (MTP-131) Business: Endocrine/Metabolic Molecular target: NA Description: Undisclosed short peptide targeting mitochondria Indication: Treat mitochondrial…

    Published on 3/9/2015
  • LJPC-501: SPA received

    La Jolla Pharmaceutical Co.(NASDAQ:LJPC), San Diego, Calif. Product: LJPC-501 Business: Cardiovascular Molecular target: NA Description: Renin-angiotensin system peptide agonist Indication: Treat catecholamine-resistant…

    Published on 3/9/2015
  • Masitinib: Phase II ongoing

    AB Science S.A.(Euronext:AB), Paris, France Product: Masitinib (Masican) (AB1010) Business: Cancer Molecular target: Stem cell factor (SCF) receptor tyrosine kinase (c-Kit) (KIT) (CD117) Description: Stem cell factor (…

    Published on 3/9/2015
  • P2B001: Completed Phase IIb enrollment

    Pharma Two B Ltd., Rehovot, Israel Product: P2B001 Business: Neurology Molecular target: Monoamine oxidase B (MAO-B); Dopamine receptor Description: Oral fixed-dose combination of pramipexole, a dopamine agonist, and …

    Published on 3/9/2015
  • SMT C1100: Phase Ib started

    Summit Therapeutics plc(LSE:SUMM; NASDAQ:SMMT), Abingdon, U.K. Product: SMT C1100 (formerly BMN 195) Business: Musculoskeletal Molecular target: Utrophin (UTRN) Description: Small molecule utrophin up-regulator …

    Published on 3/9/2015
  • TV-45070: Phase IIb start

    Teva Pharmaceutical Industries Ltd.(NYSE:TEVA), Petah Tikva, Israel Xenon Pharmaceuticals Inc.(NASDAQ:XENE), Burnaby, B.C. Product: TV-45070, Topical XEN402 Business: Neurology Molecular target: Nav1.7 (SCN9A) …

    Published on 3/9/2015
  • Vapendavir: Phase IIb started

    Biota Pharmaceuticals Inc.(NASDAQ:BOTA), Alpharetta, Ga. Product: Vapendavir (BTA798) Business: Infectious Molecular target: HRV capsid Description: Oral human rhinovirus (HRV) antiviral Indication: Treat human …

    Published on 3/9/2015
  • VB-111: Phase III start

    VBL Therapeutics Ltd.(NASDAQ:VBLT), Or Yehuda, Israel Product: VB-111 Business: Cancer Molecular target: NA Description: Non-replicating adenovector, a proprietary modified murine pre-proendothelin promoter (PPE-1-3x) …

    Published on 3/9/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993